Metabolic disorders encompass a range of conditions that disrupt normal biochemical processes, leading to imbalances in energy regulation, glucose metabolism, and lipid profiles. In companion animals, as in humans, metabolic diseases such as diabetes mellitus and obesity are increasingly prevalent, impacting quality of life and contributing to secondary health complications.

Transpharmation offers models of Type I Diabetes and obesity in dogs, each providing robust platforms for the development and assessment of metabolic therapeutics. Our Type I Diabetes model uses streptozotocin (STZ) to selectively ablate pancreatic beta cells, inducing persistent hyperglycemia and insulin deficiency that accurately reflects human Type I Diabetes pathophysiology. This model supports the evaluation of insulin replacement therapies, glucose-lowering agents, and treatments targeting diabetic complications. Separately, our obesity model involves controlled dietary protocols to induce weight gain and metabolic dysregulation in dogs, providing a relevant system for testing weight management strategies, appetite suppressants, and metabolic modulators aimed at addressing obesity-related health challenges in companion animals.

Examples of endpoints:

  • •
    Blood glucose measurement
  • •
    Continuous interstitial fluid glucose measurement
  • •
    IVGTT, OGTT and Insulin sensitivity
  • •
    Body weight and body condition scoring
  • •
    Urinalysis
  • •
    QMR, DEXA or MRI